Most American adults are not routinely screened or assessed for dementia until symptoms are apparent or readily recognizable. A wide array of innovations are now emerging that can enable dementia screening and assessment more rapidly, comprehensively, and at greater scale than typically seen today. Innovative tests, tools, and protocols are also creating capabilities to detect dementia at an early and even pre-symptomatic stage.

NEHI's Tom Hubbard discussed the innovations and their implications with leading experts in the field, including:

• Elli Kaplan, MBA, Cofounder & CEO of Neurotrack
• Vijaya Kolachalama, PhD, FAHA, Associate Professor, Boston University School of Medicine
• Jennifer Pollack, JD, Director of Access Policy, Alzheimer's Association and Alzheimer's Impact Movement
• Claire Sexton, DPhil, Senior Director of Scientific Programs & Outreach, Alzheimer's Association

Among the topics discussed were:

• The impact of new and emerging innovations in dementia screening and assessment--and in brain health assessment more broadly--in the primary care setting;
• The future use of blood-based biomarkers in dementia detection and diagnosis;
• The emerging capabilities of AI and predictive analytics to identify individuals at risk for dementia and related disorders; and
• Current and expected barriers to adoption and payer reimbursement for innovative dementia screening and assessment.

See below for the webinar recording held on October 16, 2024.